Table 2.
RR of grade ≥3 adverse events in patients with advanced gastric cancer treated with angiogenesis inhibitors
| Grade ≥3 adverse events | No. of trials | Events/total | RR (95 % CI) | P value | Analysis model | |
|---|---|---|---|---|---|---|
| Treatment group | Control group | |||||
| Decreased appetite | 5 | 55/1095 | 60/973 | 0.86 (0.61, 1.22) | 0.39 | Fixed |
| Vomiting | 5 | 62/1051 | 67/975 | 0.94 (0.48, 1.82) | 0.84 | Random |
| Anemia | 8 | 118/1419 | 125/1161 | 0.91 (0.55, 1.50) | 0.7 | Random |
| Hypertension | 6 | 105/1318 | 22/1066 | 2.85 (0.87–9.30) | 0.08 | Random |
| Hemorrhage | 4 | 27/898 | 31/698 | 0.65 (0.39–1.09) | 0.11 | Fixed |
| Thromboembolic events | 4 | 42/778 | 56/598 | 0.68 (0.46, 1.00) | 0.05 | Fixed |
| Proteinuria | 5 | 147/1218 | 141/529 | 1.07 (0.76–1.34) | 0.94 | Fixed |
| GI perforation | 3 | 12/985 | 2/496 | 4.1 (1.14–15.05) | 0.03 | Fixed |
| Neuropathy | 3 | 30/318 | 27/312 | 1.11 (0.68–1.82) | 0.67 | Fixed |
| Diarrhea | 7 | 60/1135 | 35/1044 | 1.66 (1.11, 2.50) | 0.01 | Fixed |
| Nausea | 6 | 45/996 | 58/952 | 0.77 (0.53, 1.11) | 0.16 | Fixed |
| Fatigue | 7 | 79/904 | 55/627 | 0.91 (0.44, 1.88) | 0.75 | Random |
| Leukopenia | 6 | 83/797 | 45/665 | 1.23 (0.61, 2.48) | 0.58 | Random |
| Thrombocytopenia | 5 | 33/797 | 16/665 | 1.74 (0.96, 3.12) | 0.07 | Fixed |
| Neutropenia | 7 | 217/842 | 118/711 | 1.53 (0.99, 2.37) | 0.06 | Random |
| Hand-foot syndrome | 4 | 51/711 | 14/569 | 2.83 (1.57, 5.11) | 0.0005 | Fixed |
| Electrolyte disturbance | 3 | 23/662 | 26/574 | 0.8 (0.32–1.99) | 0.63 | Fixed |
| Pain | 6 | 42/694 | 31/676 | 1.06 (0.30, 3.79) | 0.93 | Random |
| Liver damage | 4 | 56/414 | 19.287 | 1.59 (1.01, 2.51) | 0.04 | Fixed |
RR risk ratios, GI gastrointestinal